Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"

Detalles Bibliográficos
Autores principales: Khuntia, Bharat Krushna, Agarwal, Aman, Sharma, Gautam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040503/
https://www.ncbi.nlm.nih.gov/pubmed/35487344
http://dx.doi.org/10.1016/j.ctim.2022.102838
_version_ 1784694351399485440
author Khuntia, Bharat Krushna
Agarwal, Aman
Sharma, Gautam
author_facet Khuntia, Bharat Krushna
Agarwal, Aman
Sharma, Gautam
author_sort Khuntia, Bharat Krushna
collection PubMed
description
format Online
Article
Text
id pubmed-9040503
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-90405032022-04-26 Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India" Khuntia, Bharat Krushna Agarwal, Aman Sharma, Gautam Complement Ther Med Article The Author(s). Published by Elsevier Ltd. 2022-09 2022-04-26 /pmc/articles/PMC9040503/ /pubmed/35487344 http://dx.doi.org/10.1016/j.ctim.2022.102838 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Khuntia, Bharat Krushna
Agarwal, Aman
Sharma, Gautam
Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"
title Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"
title_full Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"
title_fullStr Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"
title_full_unstemmed Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"
title_short Letter to Editor on "A randomized, controlled, blinded, parallel-group, clinical trial to study the role of Ayurcov (AyurCoro3), a one-day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India"
title_sort letter to editor on "a randomized, controlled, blinded, parallel-group, clinical trial to study the role of ayurcov (ayurcoro3), a one-day regimen as an adjuvant therapy for covid-19 disease management, at dedicated covid hospital (dch) in india"
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040503/
https://www.ncbi.nlm.nih.gov/pubmed/35487344
http://dx.doi.org/10.1016/j.ctim.2022.102838
work_keys_str_mv AT khuntiabharatkrushna lettertoeditoronarandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3aonedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT agarwalaman lettertoeditoronarandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3aonedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia
AT sharmagautam lettertoeditoronarandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3aonedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia

Ejemplares similares